Comparative Pharmacology
Head-to-head clinical analysis: CLADRIBINE versus ZYNLONTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLADRIBINE versus ZYNLONTA.
CLADRIBINE vs ZYNLONTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate (ADC) consisting of a humanized anti-CD19 monoclonal antibody conjugated via a cleavable linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Upon binding to CD19-expressing cells, the conjugate is internalized and the linker is cleaved, releasing the PBD dimer, which crosslinks DNA and induces cell death.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
0.15 mg/kg intravenously every 3 weeks, up to a maximum of 9 mg per dose, until disease progression or unacceptable toxicity.
None Documented
None Documented
Clinical Note
moderateCladribine + Digoxin
"Cladribine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCladribine + Digitoxin
"Cladribine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCladribine + Deslanoside
"Cladribine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCladribine + Acetyldigitoxin
"Cladribine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Terminal elimination half-life (t½) is approximately 0.6 hours (range 0.3–1.0 hours) for the intact antibody–drug conjugate, reflecting rapid clearance; the unconjugated payload (SG3199) has a longer t½ of approximately 1–2 hours.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Primarily eliminated via biliary/fecal route (approximately 71% of administered dose recovered in feces as unchanged drug), with renal excretion accounting for a minor fraction (<10% of dose as unchanged drug in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent